Clinical Data Inc

Clinical Data — Investor Presentation (January 2006)

32 slides from Clinical Data's investor presentation, Jan 20, 2006

  1. Slide 1: Pharmacogenomics: Hope & Reality

    Clinical Data ® Pharmacogenomics: Hope & Reality Israel M. Stein MD President , CEO January 19, 2006

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The following presentation contains certain forward-looking information about Clinical Data that are intended to be covered by the safe harbor for “forward-looking statements” provided by the P

  3. Slide 3: Pharmacogenomics HOPE

    Pharmacogenomics HOPE Developing a new generation of therapeutic products that are efficacious and safe for populations that are defined by a genetic diagnostic test. Individualized drug therapies Match a patient with effective and safe medications based on genetic diagnostic tests. Personalized dis

  4. Slide 4: Biomarkers Change the Drug Response Paradigm

    Biomarkers Change the Drug Response Paradigm Efficacy/safety is enriched through patient selection Drug Response Conventional Drugs PGx/Rx Products

  5. Slide 5: Potential Benefit

    Potential Benefit Diagnosis Drug 2 Drug 3 Drug 4 Drug 1 Time Reactive Medical Care Diagnosis PGx Drug 1 Time Predictive Medical Care

  6. Slide 6: Pharmacogenomics

    Pharmacogenomics Guide clinical drug utilization to Reduce adverse events Improve patient outcomes Reduce cost Speed drug development Permit retrospective analyses of adverse events

  7. Slide 7: How Can Pharmacogenomics Contribute? Drug Class Indication % Responders

    How Can Pharmacogenomics Contribute? Drug Class Indication % Responders Biomarkers to identify those who will get the best response to a drug Beta-blockers Heart disease, HTN 65 - 85% ACE-inhibitors High blood pressure 63 - 86% AGT2R inhibitors High blood pressure 71 - 88% HMGCoA reductase inhibitor

  8. Slide 8: Adverse Drug Reactions

    Adverse Drug Reactions 5% of all hospital admissions (1.5 million cases) 106,000 deaths in USA annually 2.2 million patients suffer serious, but not deadly, side effects. Increased length of hospital stay Increased cost per patient - $2500 ADR associated costs $177 billion Pharmacogenomic safety bio

  9. Slide 9: How Can Pharmacogenomics Contribute?

    How Can Pharmacogenomics Contribute? Source: Kromite Consulting; 5 yr averages Discovery Pre-Clinical Development Phase I Phase II Phase III Approval 65% 35% 14% 12% Probability of success Recapture stalled drugs due to efficacy and/or safety issues

  10. Slide 10: Regulators and Industry Support

    Regulators and Industry Support FDA defining the regulatory terrain: Guidance for Pharmacogenomic Data Submissions issued May 2005 Seen as a key tool in streamlining the drug development process and is featured prominently in the FDA Critical Path Builds on early examples: Herceptin, Gleevec and Erb

  11. Slide 11: Clinical Data at a glance

    Recently acquired Genaissance Pharmaceuticals and Icoria 475 employees worldwide Annualized Revenues of ~$100 mln NASDAQ National Market CLDA ISO 9001, EN13485, CE, FDA, GLP, CLIA Clinical Data ®

  12. Slide 12: Mission & Strategy

    To become a leader in commercializing pharmacogenomics and clinical diagnostics Our strategic focus is to develop diagnostics that determine how a person's genetic makeup effects drug efficacy and safety Clinical Data ® Mission & Strategy

  13. Slide 13: Pipeline Reality

    Pipeline Reality Marketed Marketed Marketed Expand sales Initiate Phase II Plan PGx/Rx trial Commence Marketing Validation study TPMT Test for Drug Toxicity PGx/Rx Vilazodone Clozapine PGx 2005 2006

  14. Slide 14: Pharmacogenomics Two CNS Drugs Reality

    Pharmacogenomics Two CNS Drugs Reality Vilazodone anti-depressive Efficacy Biomarker Clozapine anti-psychotic Safety Biomarker

  15. Slide 15: Vilazodone Pharmacogenomics

    Vilazodone Pharmacogenomics Reposition a stalled compound by developing efficacy biomarkers Apply these biomarkers in subsequent trials to enrich a study with likely responders demonstrate efficacy of the drug Identify biomarkers that may be used in proving efficacy for a similar class of drugs in f

  16. Slide 16: Vilazodone

    Vilazodone Primary Indication: Treatment of depression Profile: New generation of a dual serotonergic antidepressant Mechanism of Action: Selective Serotonin Reuptake Inhibitor (SSRI) 5HT1A partial agonist Development Stage: Phase II

  17. Slide 17: Ineffective Therapies Lead to Physician and Patient Dissatisfaction

    Ineffective Therapies Lead to Physician and Patient Dissatisfaction Unsatisfactory results for 50% of patients with first line drugs Discontinuation rates and resulting relapses very high Poor differentiation of therapeutic benefit for currently marketed SSRIs Physicians are likely to adopt a test/d

  18. Slide 18: Genetic Rationale for Finding Efficacy Biomarkers

    Genetic Rationale for Finding Efficacy Biomarkers Depression is a complex genetic disease Response to SSRIs has a strong genetic component Patients who fail to respond to one SSRI will respond to another A given individual’s response predicts the same outcome in first- degree relatives A genetic mar

  19. Slide 19: Genetics of Response to SSRIs Previous Associations

    Genetics of Response to SSRIs Previous Associations Source: Reviewed in Serretti, The Pharmacogenetics Journal 2004; 233-44 Gene Allele(s) Drug(s) Endpoint(s) Fluvoxamine, Paroxetine probability of response Fluvoxamine, Paroxetine time to response Citalopram remission Fluvoxamine better response Try

  20. Slide 20: Serotonin Transporter Variability and Response to SSRIs in Caucasian Populations

    Serotonin Transporter Variability and Response to SSRIs in Caucasian Populations Study Drug p-value Smeraldi, 1998 Fluvoxamine <0.0001 (SS vs. LS/LL) Pollock, 2000 Paroxetine <0.0001 (LL vs LS/SS) Zanardi, 2000 Paroxetine 0.0001 (SS vs LS/LL) Rausch, 2002 Fluoxetine 0.02 (SS vs. LS/LL) Promoter regi

  21. Slide 21: Vilazodone: A "Stalled" Compound Ideal for Pharmacogenetic Rescue

    Vilazodone: A “Stalled” Compound Ideal for Pharmacogenetic Rescue Pre-clinical data suggest vilazodone will be a potent antidepressant with a novel mechanism of action Pre-Clinical Toxicity is acceptable Large amount of safety data show safety is acceptable for phase of development and similar to SS

  22. Slide 22: Vilazodone: A "Stalled" Compound Ideal for Pharmacogenetic Rescue

    Vilazodone: A “Stalled” Compound Ideal for Pharmacogenetic Rescue Utilize Genaissance’s HAP Database and expertise in biomarker development Diagnostic test/drug combination answers unmet medical need Pharmacogenetics can position vilazodone for successful development and as a clearly differentiated

  23. Slide 23: Clozapine

    Clozapine Develop safety biomarkers for a rare but serious adverse drug reaction Biomarker would have immediate utility as a risk assessment tool May enable a highly effective drug to reach a broader population

  24. Slide 24: Clozapine Induced Agranulocytosis (CIA)

    Clozapine Induced Agranulocytosis (CIA) Defined as an absolute Neutrophil count of <500/mm 3 Incidence of 1.3% without monitoring Incidence of 0.3%-0.4% with weekly monitoring Progression from reduction in absolute neutrophil count to agranulocytosis is ~2-5days Recovery takes 14-24 days

  25. Slide 25: Rationale for Genetic Markers for CIA

    Rationale for Genetic Markers for CIA Clozapine is considered by many to have superior efficacy in treating schizophrenia The only drug shown to be superior to standard treatment in a randomized controlled study

  26. Slide 26: Rationale for Genetic Markers for CIA

    Rationale for Genetic Markers for CIA Restricted to third-line therapy due to the risk of CIA In U.S., ~ 2.5 million patients with schizophrenia take antipsychotics ~80% are on first-line therapy; ~16% on second-line therapy Clozapine is confined to about 4% of the market “No blood, no drug” policy

  27. Slide 27: Evidence for Genetic Component to CIA

    Evidence for Genetic Component to CIA A disproportionate number of the U.S. cases occurred in patients of similar ethnic background Inter-individual variability in the onset of CIA Published evidence for genetic associations

  28. Slide 28: Select Published Associations with CIA

    Select Published Associations with CIA HLA-DRB1/B5 1 HLA-C 2 MPO 4 NQO2 3 5.95 0.01 2.85 0.02 0.04 <0.001 Raw p-value 5.30 >6 OR N Cases N Controls Gene 1 Yunis, et al. Blood 1995 2 Dettling, et al. Pharmacogenetics 2001 3 Ostrousky, et al. Tissue Antigens 2003 4 Mosyagin, et al. J Clin Psychopharm

  29. Slide 29: Goal

    Goal Discover a marker that is Found in at least 80% of patients who develop CIA Found in only 20% of patients who do not develop CIA Such a marker would lead to an ~80% reduction in CIA

  30. Slide 30: Candidate Genes

    Candidate Genes 74 candidate genes (1219 polymorphisms) Genes involved in clozapine metabolism Genes involved in promyelocytic differentiation Genes for which associations with CIA have been discovered Apply proprietary HAP Database content and haplotype analysis major histocompatibility complex, cl

  31. Slide 31: CIA Associations

    CIA Associations (33 Cases, 54 Controls) NTSR1 HLA-C HLA-DQB1 M2 and X DRD1 Gene X HLA-DQB1 M2 HLA-DQB1 M1 5.7% 0.27% 94% 36% 11.8 0.0079 0.00065 0.11% 0.12% 0.33% 0.25% 0.16% 0.06% 100 – NPV* 20.7% 37.2% 0.1% 3.9% 16.9% 39.1% % Test Positive 0.0000010 0.000051 0.0022** 0.00012 0.000013 0.000049 Raw

  32. Slide 32: Clinical Data - Pharmacogenomics: Hope & Reality

    Clinical Data ® Pharmacogenomics: Hope & Reality Israel M. Stein MD President , CEO

Clinical Data — Investor Presentation (January 2006) on 6ix